Sanofi is terminating a Phase III chronic inflammatory demyelinating polyneuropathy (CIDP) trial of riliprubart after analysis showed the drug is unlikely to show efficacy. The Phase III MOBILIZE study (NCT06290128) investigated the IgG4 humanised monoclo... See more
Gilead Sciences and MSD’s human immunodeficiency virus (HIV) once weekly tablet combination has met primary endpoints in two Phase III trials. In the 48-week ISLEND-1 (NCT06630286) and ISLEND-2 (NCT06630299) trials, the two pharmaceutical companies invest... See more
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a 10.5% weight loss in patients. Data from the VISTA and SOLSTICE trials of elecoglipron, which was licensed from E... See more
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026. While Clinical Trials Arena already wrapped up the major obesity readouts, there were also significant updates in the type 1 and typ... See more
Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts. The data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking p... See more
